

## ORIGINAL ARTICLE

Kensei Tsuzaka · Natsuko Onoda · Keiko Yoshimoto  
Yumiko Setoyama · Katsuya Suzuki · Ming Pang  
Tohru Abe · Tsutomu Takeuchi

## T-cell receptor $\zeta$ mRNA with an alternatively spliced 3' untranslated region is generated predominantly in the peripheral blood T cells of systemic lupus erythematosus patients

Received: September 17, 2001 / Accepted: December 17, 2001

**Abstract** To investigate the mechanism of the down-regulation of T-cell receptor  $\zeta$  chain (TCR $\zeta$ ) expression in the peripheral blood T cells (PBTs) of systemic lupus erythematosus (SLE) patients, we analyzed the 3' untranslated region (3'UTR) of TCR $\zeta$  mRNA, because the 3'UTR in mRNA is responsible for posttranscriptional regulation. Use of the reverse transcriptase polymerase chain reaction (RT-PCR) to amplify the 917bp TCR $\zeta$  3'UTR cDNA demonstrated that the short variant cDNA (355bp), expressed as an alternatively spliced 3'UTR with 562-bp deletion, was predominated in the PBTs of 11 of 14 SLE patients, whereas mainly the wild-form cDNA (917bp) was detected in the PBTs of seven negative controls (two systemic sclerosis patients, five normal controls) and in two T-cell line hybridomas. Semiquantitative PCR also revealed the predominant expression of the TCR $\zeta$  mRNA with alternatively spliced 3'UTR (TCR $\zeta$  mRNA/as-3'UTR), and a decreased expression of TCR $\zeta$  mRNA with the wild form 3'UTR (TCR $\zeta$  mRNA/w-3'UTR) in SLE T cells. However, there was no difference in the expression of the open reading frame (ORF) TCR $\zeta$  mRNA between the negative controls and SLE patients. The TCR $\zeta$  protein expression level according to Western blot analysis correlated well with that of TCR $\zeta$  mRNA/w-3'UTR ( $r = 0.931$ ) and reversibly with TCR $\zeta$  mRNA/as-3'UTR ( $r = -0.614$ ), but not with ORF TCR $\zeta$  mRNA ( $r = -0.296$ ). It can be concluded that the reduced expression of TCR $\zeta$  mRNA/w-3'UTR and the predominant expression of TCR $\zeta$  mRNA/as-3'UTR lead to downregulation of the TCR $\zeta$  protein in SLE T cells.

**Key words** Alternative splicing · Autoimmune disease · CD3 · Signal transduction · T lymphocytes

### Introduction

Systemic lupus erythematosus (SLE) is well known as one of the prototype systemic autoimmune diseases.<sup>1</sup> The signal transduction pathway via the T-cell receptor (TCR) has been shown to be altered in MRL *lpr/lpr* mice.<sup>2</sup> Although the *lpr* gene is characterized by a retrotransposone that disrupts *fas* expression and leads to deficient apoptosis and lymphadenopathy, recent studies have demonstrated that background genes in SLE play an important role in developing autoimmune phenomena and autoimmune diseases.<sup>3–8</sup> Defects in signal transduction through the TCR–CD3 complex may cause T-cell dysfunction and autoimmunity in NOD mice as well as in MRL *lpr/lpr* mice.<sup>9–11</sup> Several studies, including our own, have demonstrated the functional defect of early signaling molecules on peripheral blood T cells (PBTs) as a cause of T-cell dysfunction in human SLE,<sup>12–14</sup> and it has been suggested that the T-cell receptor  $\zeta$  chain (TCR $\zeta$ ) is coupled to the signal transduction machinery in T cells, and that decreased or aberrant expression of TCR $\zeta$  may cause T-cell dysfunction, loss of tolerance, or the development of autoimmunity.<sup>15</sup> We recently reported that tyrosine phosphorylation and expression of TCR $\zeta$  were significantly decreased or absent in more than half of SLE patients, and that several patients exhibited some alterations in the TCR $\zeta$  mRNA open reading frame (ORF), such as exon 7 skipping or point mutations.<sup>16,17</sup> However, as the frequency of the alteration in the ORF TCR $\zeta$  mRNA is low in comparison with the decrease in TCR $\zeta$  protein expression, we attempted to explore alternative mechanisms for the decreased TCR $\zeta$  expression in SLE. We particularly focused on the 3' untranslated region (3'UTR) of TCR $\zeta$  mRNA, since we had concentrated on the ORF in the TCR $\zeta$  mRNA in our previous studies.<sup>16,17</sup> Since the 3'UTR of mRNA has been reported to play a pivotal role in posttranscriptional regulation by altering the mRNA stability and affecting the transportation and localization of mRNA, we analyzed the 3'UTR of TCR $\zeta$  mRNA in SLE patient PBTs in this study. Here we report finding that the TCR $\zeta$  mRNA with a short spliced variant of the

K. Tsuzaka (✉) · N. Onoda · K. Yoshimoto · Y. Setoyama · K. Suzuki · M. Pang · T. Abe · T. Takeuchi  
Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School, 1981 Kamoda, Kawagoe 350-8550, Japan  
Tel. +81-49-228-3400; Fax +81-49-226-5274  
e-mail: kentsu@saitama-med.ac.jp

3'UTR was predominantly generated in SLE, whereas the expression of the TCR $\zeta$  mRNA with wild-form 3'UTR was reduced. Moreover, TCR $\zeta$  protein expression was found to be well correlated with the expression of the TCR $\zeta$  mRNA with wild-form 3'UTR but not with the TCR $\zeta$  mRNA ORF, suggesting that it might represent a novel mechanism for the decreased expression of TCR $\zeta$  in SLE.

## Methods

### Patient selection

Fourteen Japanese systemic lupus erythematosus (SLE) patients who met the revised 1982 American College of Rheumatology (ACR, formerly the American Rheumatism Association) criteria for SLE<sup>18</sup> were selected for analysis of their TCR $\zeta$  mRNA. Five normal healthy Japanese controls and two Japanese systemic sclerosis (SSc) patients who met the criteria for SSc<sup>19</sup> were included as negative controls.

### Isolation of peripheral blood T cells

Peripheral blood (20ml) was collected in a preheparinized tube, and peripheral blood mononuclear cells were isolated by Ficoll-Hypaque density-gradient centrifugation (Pharmacia Biotechnology, Uppsala, Sweden). The cell suspensions were passed over a nylon-wool column to yield a T-cell-enriched population, and the cell population obtained was more than 92% reactive to anti-CD3 (UCHL1:IgG1).

### Western blot

PBTs ( $1 \times 10^7$  cells) were lysed with 1ml lysis buffer (10mM Tris-HCl, pH 8.0, 150mM NaCl, 1% NP-40, 10mM ethylenediaminetetraacetate (EDTA), 1mM sodium orthovanadate, 1mM phenylmethylsulfonyl fluoride (PMSF), 10 $\mu$ g/ml aprotinin, and 10 $\mu$ g/ml leupeptin) at 4°C for 15 min, and disrupted by sonication. After centrifuging at 10000g for 5 min, the supernatant was electrophoresed on a 15% sodium dodecyl sulfate (SDS)-polyacrylamide gel. The proteins were electrophoretically blotted onto PVDF membranes (Millipore, Bedford, MA, USA), and the membranes were soaked at 37°C for 1h in blocking agents (Blockace; Dainippon Pharmaceuticals, Tokyo, Japan) and incubated with a mouse monoclonal antihuman TCR $\zeta$  antibody TIA-2 (Coulter Immunology, Hialeah, FL, USA) at 16°C for 1h. After washing three times, the membranes were incubated with the horseradish peroxidase (HRP)-conjugated antimouse IgG (Amersham, Amersham, UK), and after washing three more times, the signals were detected by chemiluminescence-enhancing reagents (Amersham). Treated membranes were visualized on ECL X-ray film (Amersham). The density of the specific bands was quantified by scanning with a Scan Jet II (Hewlett Packard) and NIH Image Software (version 1.56).

### Primer design for PCR


Primers to amplify the TCR $\zeta$  open reading frame (ORF) cDNA (605bp of the expected size) were arranged on the upstream and downstream sides of the ORF of TCR $\zeta$  mRNA according to the nucleotide sequence reported by Weissman et al.<sup>20</sup> [5'-TCAGCCTCTGCCTCCCAGCCTC TTTCT-3' (+33 to +59) and 5'-ATGCTTCATCCTGTGT CTCATAATCTG-3' (+638 to +612), respectively]. Primers for the TCR $\zeta$  3'UTR cDNA (917bp of the expected size) were arranged on the 5' end of exon 6 and the 3' end of exon 8 [5'-TCTCAGTACAGCCACCAAGGACACC-3' (+437 to +461) and 5'-CGTGAAGTGAATCAACGG CCTCCTCTT-3' (+1354 to +1328), respectively] (Fig. 1). As a positive control, glyceraldehyde 3-phosphate dehydrogenase (G3PDH) cDNA (983bp of the expected size) was amplified by PCR using primers specific for G3PDH (Clontech Laboratories, Palo Alto, CA, USA).

### RT-PCR

Messenger RNA was isolated from PBTs with an mRNA isolation kit (Pharmacia Biotechnology) immediately after separating them from peripheral blood. The mRNA was then converted to whole cDNA by reverse transcriptase according to the method described previously.<sup>17</sup> Using 5 $\mu$ l of the whole cDNA derived from the PBTs as the template, the cDNA was amplified by PCR with specific primers and Taq DNA polymerase (Perkin-Elmer, Foster City, CA, USA). The PCR conditions were denaturation at 95°C for 30s, annealing at 55°C for 30s, and extension at 72°C for 1min for a total of 38 cycles. Five microliters of the PCR product was analyzed by 1.5% agarose gel electrophoresis.

### Semiquantitative PCR for TCR $\zeta$ cDNA

TCR $\zeta$  ORF cDNA, TCR $\zeta$  3'UTR cDNA, and G3PDH cDNA from PBTs were amplified by PCR as described above, and electrophoresed in 1.5% agarose gels under standardized conditions. Aliquots were taken from the reaction mixture every three cycles, starting with cycle 21. After staining with ethidium bromide, the UV-induced fluorescence of specific bands was quantified in relation to the DNA molecular weight marker by scanning with Scan Jet II (Hewlett Packard) and NIH Image Software (version



**Fig. 1.** Primers for amplifying TCR $\zeta$  cDNA in reverse transcriptase polymerase chain reaction (RT-PCR). Primers for amplifying TCR $\zeta$  open reading frame (ORF) cDNA were arranged on the upstream and downstream of the ORF of TCR $\zeta$  mRNA (dotted arrows). Primers for TCR $\zeta$  3'UTR cDNA were arranged on the 5' end of exon 6 and the 3' end of exon 8 (solid arrows). The expected sizes of TCR $\zeta$  ORF cDNA and 3'UTR cDNA were 605 bp and 917 bp, respectively.

1.56), and the relative OD values were graphically evaluated. We calculated the difference in the number of cycles ( $\Delta n$ ) needed to reach identical yields of specific PCR products as compared with the internal G3PDH standard according to the method described by Kinoshita et al.<sup>21</sup>

### Nucleotide sequencing

PCR products were electrophoresed in 1.5% agarose gels, and the specific DNA bands were eluted from the gels with a DNA elution kit (GENECLEAN II Kit, BIO 101, Vista, CA, USA). The isolated DNA was then ligated into the polylinker regions of pT7Blue T-vector (Novagen, Madison, WI, USA). The nucleotide sequences of the insert DNA were determined using the dideoxychain termination method<sup>22</sup> with T7 DNA polymerase<sup>23</sup> (US Biochemical, Cleveland, OH, USA).

### Statistical analysis

Statistical significance was calculated by one-way ANOVA and the Mann–Whitney *U*-test for unpaired data by using Statview software (version 4.5, Abacus, Berkeley, CA, USA). A level of  $P < 0.05$  accepted as being statistically significant.

## Results

### RT-PCR of TCR $\zeta$ 3'UTR cDNA


Whole mRNA was isolated from PBTs (14 SLE patients, 2 SSc patients, and 5 normal controls) and two human leukemic T cell lines (Jurkat and MOLT4). Whole mRNA

was converted to whole cDNA by reverse transcriptase, and the TCR $\zeta$  3'UTR cDNA was amplified by PCR with primers arranged on the 5' end of exon 6 and the 3' end of exon 8. As shown in Fig. 2, the agarose gel electrophoresis demonstrated that a short cDNA (355bp) was detected in addition to the normal-sized cDNA (917bp). The short cDNA seemed to predominate over the normal-sized cDNA in 11 of the 14 SLE patients (TaS, KaM, YaK, NoY, TaR, SeK, YoT, MaS, NaY, NiS, and HaE), and six of the SLE patients (KaM, SeK, MaS, NaY, NiS, and HaE) had only the short cDNA. On the other hand, the normal-sized cDNA was amplified dominantly in all five normal controls, the two SSc patients, and the two T cell lines.

### Nucleotide sequence of the TCR $\zeta$ 3'UTR cDNA in SLE patients

TCR $\zeta$  3'UTR cDNA was amplified by PCR of SLE patient TaS. After electrophoresis on 1.5% agarose gel, the normal-sized (917bp) and short (355bp) DNA bands were cut out of the gels and purified. The isolated DNA was then ligated into the polylinker regions of the pT7Blue T-vector to determine the nucleotide sequence. The nucleotide sequence of the normal-sized (917bp) cDNA completely matched the sequence reported by Weissman et al.,<sup>20</sup> and this cDNA encoded exon 7 and exon 8, including the 3'UTR of TCR $\zeta$  mRNA, whereas the short (355bp) cDNA was 562-bp shorter than the normal-sized cDNA according to the nucleotide sequence (Fig. 3). Since the sequence of the 562-bp deleted portion included both the splicing donor and the acceptor sites ["GT" (+671 to +672) and "AG" (+1231 to +1232)] at the 3' and 5' end, respectively, the short (355bp) cDNA may represent an alternatively spliced variant that appeared to result from splicing at these sites. On the other hand, no polymorphism or mutations were found in the


**Fig. 2.** PCR amplification of TCR $\zeta$  3'UTR cDNA. Whole mRNA was isolated from the peripheral blood T cells (PBTs) of 14 systemic lupus erythematosus (SLE) patients and 9 negative controls (two SSc patients (SSc1, SSc2), five normal controls, two leukemic T-cell lines (Jurkat and MOLT4)) and converted to the whole cDNA by reverse transcriptase. TCR $\zeta$  3'UTR cDNA was then amplified by PCR, and the PCR products were analyzed in the 1.5% agarose gels. *MWM* indicates the DNA molecular weight marker. As shown in this figure, a short-sized TCR $\zeta$  3'UTR cDNA (indicated as 355 bp) was detected as well as the normal-sized cDNA (indicated as 917 bp).



TCR $\zeta$  genomic DNA around these splicing sites by analyzing the nucleotide sequence of genomic DNA.

### Semiquantitative PCR for TCR $\zeta$ 3'UTR cDNA


We then quantitatively investigated whether the TCR $\zeta$  mRNA with alternatively spliced short 3'UTR is predominantly expressed in SLE patient T cells, and the TCR $\zeta$



**Fig. 3.** Splicing donor and acceptor sites in the TCR $\zeta$  mRNA 3'UTR. TCR $\zeta$  3'UTR cDNA from SLE patient TaS was amplified by PCR. After electrophoresis in a 1.5% agarose gel, the normal-sized (917 bp) and the short-sized (355 bp) DNA bands were cut out of the gels and purified. Isolated cDNA was ligated into the polylinker regions of pT7Blue T-vector, and the nucleotide sequences of the insert DNA were determined by using the dideoxychain termination method with T7 DNA polymerase. **a** The nucleotide sequence of the normal-sized (917 bp) TCR $\zeta$  3'UTR cDNA perfectly matched the sequence reported by Weissman et al.<sup>20</sup> and included both the splicing donor (GT) and the acceptor (AG) sites. **b** The short (355 bp) cDNA was 562-bp shorter than the normal-sized cDNA and encoded a part of the TCR $\zeta$  mRNA 3'UTR which was expressed as a result of an alternative splicing at these splicing sites.

mRNA with wild-form 3'UTR is decreased by using semiquantitative PCR. TCR $\zeta$  ORF cDNA, TCR $\zeta$  3'UTR cDNA, and G3PDH cDNA from seven SLE patients and four normal controls were then amplified by PCR and electrophoresed in 1.5% agarose gels. Figure 4 shows representative results of the semiquantitative PCR from a normal control and SLE patient NoY. The number of PCR cycles required for amplification of similar levels of cDNA coding for G3PDH among TCR $\zeta$  ORF cDNA, TCR $\zeta$  3'UTR cDNA (917 bp), and TCR $\zeta$  3'UTR cDNA (355 bp) ( $\Delta_1$ ,  $\Delta_2$ ,  $\Delta_3$ , respectively) was compared. The results showed that similar levels of TCR $\zeta$  ORF cDNA were amplified in the normal control and in SLE patient NoY ( $\Delta_1 = 4.4$  vs.  $\Delta_1 = 4.1$ ) under these experimental conditions. TCR $\zeta$  3'UTR cDNA (917 bp) was expressed in the normal control ( $\Delta_2 = 5$ ), whereas TCR $\zeta$  3'UTR cDNA (355 bp) was undetectable ( $\Delta_3 > 33$ ). On the other hand, no TCR $\zeta$  3'UTR cDNA (917 bp) was expressed ( $\Delta_2 > 33$ ) in SLE patient NoY, and TCR $\zeta$  3'UTR cDNA (355 bp) was predominantly expressed ( $\Delta_3 = 7.1$ ). Since the levels of expression of TCR $\zeta$  ORF cDNA, TCR $\zeta$  3'UTR cDNA (917 bp), and TCR $\zeta$  3'UTR cDNA (355 bp) correspond to that of TCR $\zeta$  mRNA coding for ORF (ORF TCR $\zeta$  mRNA), TCR $\zeta$  mRNA with wild-form 3'UTR (TCR $\zeta$  mRNA /w-3'UTR), and TCR $\zeta$  mRNA with alternatively spliced 3'UTR (TCR $\zeta$  mRNA/as-3'UTR), respectively, these results suggest that TCR $\zeta$  mRNA/w-3'UTR was predominantly expressed in the normal control, whereas TCR $\zeta$  mRNA/as-3'UTR was predominant in SLE patient NoY.

We also compared the levels of expression of each TCR $\zeta$  mRNA in seven SLE patients and in four normal controls.



**Fig. 4.** Semiquantitative PCR for the TCR $\zeta$  cDNA. TCR $\zeta$  ORF cDNA, TCR $\zeta$  3'UTR cDNA, and G3PDH cDNA of PBTs from a normal control and from SLE patient NoY were amplified by PCR. Aliquots were taken from the reaction mixture every three cycles, beginning with cycle 21. After electrophoresing the aliquots in 1.5% agarose gels containing ethidium bromide, UV-induced fluorescence of specific bands [G3PDH cDNA (*open squares*), TCR $\zeta$  ORF cDNA (*open circles*), 917 bp TCR $\zeta$  3'UTR cDNA (*solid circles*), 355 bp TCR $\zeta$

3'UTR cDNA (*solid triangles*)] were quantified as the relative OD value in relation to the DNA molecular weight marker. The relative OD values were graphically evaluated as shown in this figure. Differences in the numbers of cycles ( $\Delta n$ ) needed to reach identical yields of the PCR products as compared with G3PDH cDNA were calculated according to the method described by Kinoshita et al.<sup>21</sup> ( $\Delta_1$ , TCR $\zeta$  ORF cDNA;  $\Delta_2$ , TCR $\zeta$  3'UTR cDNA (917 bp);  $\Delta_3$ , TCR $\zeta$  3'UTR cDNA (355 bp))


For cases needing more than 33 cycles, we calculated as 34 cycles in the statistical analysis. As shown in Table 1, expression of TCR $\zeta$  mRNA/w-3'UTR in all of the normal controls ( $\Delta_2 = 4.4 \pm 0.4$ ) was significantly ( $P < 0.01$ ) higher than that estimated in the SLE patients ( $\Delta_2 = 26.4 \pm 13.0$ ). In contrast, TCR $\zeta$  mRNA/as-3'UTR was strongly detected ( $P < 0.05$ ) in the SLE patients ( $\Delta_3 = 6.0 \pm 1.9$ ) compared with the normal controls ( $\Delta_3 = 20.2 \pm 15.9$ ). It is especially noteworthy that no TCR $\zeta$  mRNA/w-3'UTR was detected ( $\Delta_2 > 33$ ) in five SLE patients (NaY, NoY, YoT, KaM, and MaS). The level of expression of ORF TCR $\zeta$  mRNA, on the other hand, did not differ between the normal controls ( $\Delta_1 = 3.7 \pm 0.6$ ) and the SLE patients ( $\Delta_1 = 3.5 \pm 0.6$ ).

#### Western blot analysis of TCR $\zeta$ protein expression in SLE T cells

To investigate the relationship between the expression of TCR $\zeta$  protein and mRNA, levels of expression of TCR $\zeta$  protein were quantified by Western blot analysis in the PBTs of seven SLE patients and four normal controls by semiquantitative PCR analysis, as described above. As shown in Fig. 5, TCR $\zeta$  was detected as an 18-kD protein band with a monoclonal antihuman TCR $\zeta$  antibody TIA-2. The OD value of the TCR $\zeta$  in the PBTs of seven SLE patients was significantly ( $P < 0.001$ ) lower (range 5–60, mean  $\pm$  SD  $23 \pm 21$ ) than in the normal controls (range 70–99, mean  $\pm$  SD  $84 \pm 12$ ).

To confirm that TCR $\zeta$  protein expression was affected by transcriptional or post-transcriptional regulation, we compared the density of TCR $\zeta$  in Western blot analysis with the level of expression of each TCR $\zeta$  mRNA (ORF TCR $\zeta$  mRNA, TCR $\zeta$  mRNA/w-3'UTR, and TCR $\zeta$  mRNA/as-3'UTR) in the seven SLE patients and four normal controls. We evaluated the level of mRNA expression as  $1/\Delta n$  by the semiquantitative PCR method described above. As shown in Fig. 6, the TCR $\zeta$  protein expression

level correlated well with that of TCR $\zeta$  mRNA/w-3'UTR ( $r = 0.931$ ) and reversibly with TCR $\zeta$  mRNA/as-3'UTR ( $r = -0.614$ ), whereas they were unassociated with that of ORF TCR $\zeta$  mRNA ( $r = -0.296$ ). These findings suggested that expression of the wild-form 3'UTR in the TCR $\zeta$  mRNA, but not expression of the ORF region, correlated well with that of TCR $\zeta$  protein. These results also appear to indicate that TCR $\zeta$  expression in SLE patient T cells was downregulated because of a reduced expression of wild-form 3'UTR and the predominant expression of the alternatively spliced short 3'UTR. Furthermore, steroid doses and the SLE disease activity index (SLEDAI) of the SLE patients observed in this study were not associated with the expression of TCR $\zeta$  protein, TCR $\zeta$  mRNA/w-3'UTR, TCR $\zeta$  mRNA/as-3'UTR, or that of ORF TCR $\zeta$  mRNA (data not shown). Based on these observations, it can be concluded that expression of TCR $\zeta$  protein in T cells is influenced by posttranscriptional regulation.




**Fig. 5.** Western blot analysis of TCR $\zeta$  protein expression by SLE T cells. PBT lysates from four normal controls and seven SLE patients were electrophoresed in 15% sodium dodecyl sulfate (SDS)-polyacrylamide gels and blotted onto a PVDF membrane. The membranes were incubated with a mouse monoclonal antihuman TCR $\zeta$  antibody TIA-2 and then with HRP-conjugated antimouse IgG. After treatment with chemiluminescence-enhancing reagents, the membranes were visualized on enhanced chemiluminescence (ECL) X-ray films, and the density of 18kD TCR $\zeta$  protein bands (arrow) was quantified as relative OD values

**Table 1.** Semiquantitative PCR for TCR $\zeta$  cDNA

	$\Delta_1$ TCR $\zeta$ ORF cDNA	$\Delta_2$ TCR $\zeta$ 3'UTR cDNA (917 bp)	$\Delta_3$ TCR $\zeta$ 3'UTR cDNA (355 bp)
Normal			
1	4.4	5	>33
2	2	3.5	>33
3	3.8	4	6.5
4	4.5	5	6.3
Mean $\pm$ SD	$3.7 \pm 0.6$	$4.4 \pm 0.4$	$20.2 \pm 15.9$
SLE			
NaY	3.3	>33	8.5
NoY	4.1	>33	5
YoT	1	>33	5
KaM	4	>33	5
MaS	1.5	>33	9
NiS	5.3	8.8	4
TaS	5	6	5.5
Mean $\pm$ SD	$3.5 \pm 0.6$	$26.4 \pm 13.0$	$6.0 \pm 1.9$

PCR, polymerase chain reaction; TCR $\zeta$ , T-cell receptor  $\zeta$ ; ns, not significant




**Fig. 6.** The relationship between the expression of TCR $\zeta$  protein and mRNA. Messenger RNA expression was estimated as  $1/\Delta n$  by the semiquantitative PCR method described above. The OD values of TCR $\zeta$  in Western blot analysis were compared with the level of expres-

sion of TCR $\zeta$  mRNA (**a** TCR $\zeta$  ORF mRNA; **b** TCR $\zeta$  mRNA/w-3'UTR; **c** TCR $\zeta$  mRNA/as-3'UTR) in seven SLE patients (*closed circles*) and four normal controls (*open circles*)

## Discussion

In this study, RT-PCR demonstrated that the short TCR $\zeta$  3'UTR cDNA (355 bp) predominated in the T-cells of most of the SLE patients, whereas the normal-sized TCR $\zeta$  3'UTR cDNA (917 bp) predominated in all five normal controls, two SSc patients, and the two leukemic T-cell lines. TCR $\zeta$  mRNA 3'UTR originally included "GT" and "AG," which correspond to a splicing donor site and an acceptor site.<sup>24</sup> Comparison of the nucleotide sequence of these two cDNAs suggested that the 355-bp cDNA fragment was expressed as an alternatively spliced TCR $\zeta$  mRNA 3'UTR as a result of a splicing out of the 562-bp fragment at these sites (Fig. 7). Although no genomic DNA mutations involving these splicing sites were detected in this study, some other mechanisms might be responsible for the TCR $\zeta$  mRNA/as-3'UTR expression in SLE T cells. Since the RT-PCR method applied at just one point in the cycle is unsuitable for quantification of mRNA expression, we analyzed the mRNA level by semiquantitative PCR. The results revealed the predominant expression of TCR $\zeta$  mRNA/as-3'UTR in SLE T cells and the decreased expression of TCR $\zeta$  mRNA/w-3'UTR. We previously reported that TCR $\zeta$  expression was significantly decreased or absent in SLE patients' T cells,<sup>16</sup> and in this study Western blot analysis yielded the same results. However, the observation that expression of ORF TCR $\zeta$  mRNA did not differ in the normal controls and the SLE patients suggested that a *cis*-acting element or *trans*-acting factor in the 5'UTR of the TCR $\zeta$  gene is not associated with the downregulation of TCR $\zeta$  protein in SLE patient T cells. Of even greater interest, TCR $\zeta$  protein expression in the Western blot analysis correlated well with the expression of TCR $\zeta$  mRNA/w-3'UTR and did so reversibly with TCR $\zeta$  mRNA/as-3'UTR but not with ORF TCR $\zeta$  mRNA. These findings might suggest that the 562-bp region in the 3'UTR of TCR $\zeta$  mRNA is important for TCR $\zeta$  protein expression, and that SLE patient T cells whose TCR $\zeta$  mRNA 3'UTR lacks this region may have low levels of TCR $\zeta$  protein. From our observations that SLE patients with low expression levels of TCR $\zeta$  protein showed unusual clinical findings, including



**Fig. 7.** Alternatively spliced 3'UTR of TCR $\zeta$  mRNA in the T cells of SLE patients. Based on our observations, in the T cells of SLE patients, the dominant expression of TCR $\zeta$  mRNA/as-3'UTR which is lacking 562 bp and the decreased expression of TCR $\zeta$  mRNA/w-3'UTR may lead to a decrease or absence of expression of TCR $\zeta$  protein

antiphospholipid antibodies, facial erythema, or possible vasculitic lesions (unpublished data), SLE patients with the alternatively spliced form of TCR $\zeta$  mRNA 3'UTR could also present similar clinical findings.

The 3'UTR in mRNA has generally been reported to play a pivotal role in post-transcriptional regulation by altering mRNA stability, and affecting the transportation and localization of mRNA. Messenger RNA 3'UTR contains *cis*-acting elements, i.e., adenosine-uridine (A-U)-rich elements, which bind to *trans*-acting proteins and participate in either the stabilization or destabilization of transcripts. Vascular endothelial growth factor (VEGF) and Na<sup>+</sup>-independent GLUT1 glucose transporter transcripts have been reported to be stabilized in hypoxia through a mechanism that appears to involve A-U-rich elements located within 3'UTR and that bind to cytoplasmic proteins to form hypoxia-inducible RNA-protein complexes.<sup>25,26</sup> Boado and Partridge<sup>25</sup> reported that a 10-nucleotide *cis*-acting element that is conserved among species is responsible for increased GLUT1 gene expression via enhanced GLUT1 mRNA stabilization. Ainger et al.,<sup>27</sup> on the other hand, reported that the 21-nucleotide RNA transport signal (RTS), which is also conserved among species, and the 344-nucleotide RNA localization region (RLR) are responsible for RNA transportation and localization.

The TCR $\zeta$  mRNA 3'UTR also contains a 31-nucleotide sequence (5'-CTCCTGCTGTAATTGGCTTCTGTTGTCAC-3') (from +973 to +1003) that is conserved only in the TCR $\zeta$  mRNA 3'UTR of a few species (human, mouse, rat, and bovine), and this region was not included in the TCR $\zeta$  mRNA/as-3'UTR in SLE patient T cells. If this conserved region is associated with RNA stabilization, transportation, or localization, its absence in 3'UTR is a plausible mechanism of TCR $\zeta$  downregulation or absence in SLE T cells. Studies to determine how this region influences TCR $\zeta$  protein expression are underway in our laboratory.

**Acknowledgments** This work was supported by grants from Grant-in-Aid for Scientific Research (C), the Ministry of Education, Science and Culture, and grants from the Ministry of Health and Welfare, Japan, and the Maruki Memorial Research Foundation.

## References

- Mills JA. Systemic lupus erythematosus. *N Engl J Med* 1994;30:1871-9.
- Samelson LE, Davidson WF, Morse HC 3d, Klausner RD. Abnormal tyrosine phosphorylation on T-cell receptor in lymphoproliferative disorders. *Nature* 1986;324:674-6.
- Tsao BP, Cantor RM, Kalunian KC, Chen CJ, Badsha H, Singh R, et al. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. *J Clin Invest* 1997;99:725-31.
- Davies EJ, Tikly M, Wordsworth BP, Ollier WE. Mannose-binding protein gene polymorphism in South African systemic lupus erythematosus. *Br J Rheumatol* 1998;37:465-6.
- Tsao BP, Cantor RM, Grossman JM, Shen N, Teophilov NT, Wallace DJ, et al. PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus. *J Clin Invest* 1999;103:1135-40.
- Moser KL, Neas BR, Salmon JE, Yu H, Gray-McGuire C, Asundi N, et al. Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. *Proc Natl Acad Sci USA* 1998;95:14869-74.
- Gaffney PM, Kearns GM, Shark KB, Ortmann WA, Selby SA, Malmgren ML, et al. A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families. *Proc Natl Acad Sci USA* 1998;95:14875-9.
- Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, et al. *Fc gamma RIIA* alleles are heritable risk factors for lupus nephritis in African-Americans. *J Clin Invest* 1996;97:1348-54.
- Zipris D, Lazarus AH, Crow AR, Hadzija M, Delovitch TL. Defective thymic T cell activation by concanavalin A and anti-CD3 in autoimmune nonobese diabetic mice. Evidence for thymic T cell anergy that correlates with the onset of insulinitis. *J Immunol* 1991;146:3763-71.
- Berman MA, Sandborg CI, Wang Z, Imfeld KL, Zaldivar F Jr, Dadufalza V, et al. Decreased IL-4 production in new onset type I insulin-dependent diabetes mellitus. *J Immunol* 1996;157:4690-6.
- Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. *Nature* 1998;39:177-81.
- Dayal AK, Kammer GM. The T cell enigma in lupus. *Arthritis Rheum* 1996;9:23-33.
- Sierakowski S, Kucharz EJ, Lightfoot RW, Goodwin JS. Impaired T-cell activation in patients with systemic lupus erythematosus. *J Clin Immunol* 1989;9:469-76.
- Takeuchi T, Pang M, Amano K, Koide J, Abe T. Reduced protein tyrosine phosphatase (PTPase) activity of CD45 on peripheral blood lymphocytes in patients with systemic lupus erythematosus (SLE). *Clin Exp Immunol* 1997;109:20-6.
- Rapoport MJ, Lazarus AH, Jaramillo A, Speck E, Delovitch TL. Thymic T cell anergy in autoimmune nonobese diabetic mice is mediated by deficient T cell receptor regulation of the pathway of p21 ras activation. *J Exp Med* 1993;177:1221-6.
- Takeuchi T, Tsuzaka K, Pang M, Amano K, Koide J, Abe T. TCR $\zeta$  chain lacking exon 7 in two patients with systemic lupus erythematosus. *Int Immunol* 1998;10:911-21.
- Tsuzaka K, Takeuchi T, Onoda N, Pang M, Abe T. Mutations in T cell receptor  $\zeta$  chain mRNA of peripheral T cells from systemic lupus erythematosus. *J Autoimmun* 1998;11:381-5.
- Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;25:1271-7.
- Masi AT, Rodnan GP, Medsger TA Jr. Preliminary criteria for the classification of systemic sclerosis (scleroderma). *Arthritis Rheum* 1980;23:581-90.
- Weissman AM, Hou D, Orloff DG, Modi WS, Seunanez H, O'Brien SJ, et al. Molecular cloning and chromosomal localization of the human T-cell receptor  $\zeta$  chain: distinction from the molecular CD3 complex. *Proc Natl Acad Sci USA* 1988;85:9079-83.
- Kinoshita T, Imamura J, Nagai H, Shimotohno K. Quantification of gene expression over a wide range by the polymerase chain reaction. *Anal Biochem* 1992;206:231-5.
- Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain terminating inhibitors. *Proc Natl Acad Sci USA* 1977;74:5463-7.
- Dale RMK, McClure BA, Houchins JP. A rapid single-stranded cloning strategy for producing a sequential series of overlapping clones for use in DNA sequencing: application to sequencing the corn mitochondrial 18S rDNA. *Plasmid* 1985;13:31-8.
- Mount SM. A catalogue of splice junction sequences. *Nucleic Acids Res* 1982;10:459-72.
- Boado RJ, Pardridge WM. Ten nucleotide *cis* element in the 3'-untranslated region of the GLUT1 glucose transporter mRNA increases gene expression via mRNA stabilization. *Brain Res Mol Brain Res* 1998;59:109-13.
- Levy AP, Levy NS, Goldberg MA. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. *J Biol Chem* 1996;271:25492-7.
- Ainger K, Avossa D, Diana AS, Barry C, Barbarese E, Carson JH. Transport and localization elements in myelin basic protein mRNA. *J Cell Biol* 1997;138:1077-87.